B
BioDelivery Sciences International Inc
F:BD5
BioDelivery Sciences International Inc
F:BD5
Price:
5.05
EUR
Market Cap:
€521.3m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
B
|
BioDelivery Sciences International Inc
F:BD5
|
US |
|
J
|
JF Wealth Holdings Ltd
HKEX:9636
|
CN |
|
M
|
Marlborough Wine Estates Group Ltd
NZX:MWE
|
NZ |
|
S
|
Synergetic Auto Performance PCL
SET:ASAP
|
TH |
|
G
|
GTM Holdings Corp
TWSE:1437
|
TW |
|
Donkeyrepublic Holding A/S
F:6UJ
|
DK |
|
MNC Asia Holding Tbk PT
IDX:BHIT
|
ID |
|
Chongqing Machinery & Electric Co Ltd
HKEX:2722
|
CN |
|
T
|
TriMas Corp
NASDAQ:TRS
|
US |
|
Z
|
Zhejiang HangKe Technology Incorporated Co
SSE:688006
|
CN |
|
T
|
TOT BIOPHARM International Co Ltd
HKEX:1875
|
CN |
|
A
|
Atreyu Capital Markets Ltd
TASE:ATRY
|
IL |
|
SAI Leisure Group Co Ltd
HKEX:1832
|
HK |
|
S
|
Surteco Group SE
SWB:SUR
|
DE |
|
K
|
Konsortium Transnasional Bhd
KLSE:KTB
|
MY |
|
L
|
Lpi Capital Bhd
KLSE:LPI
|
MY |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of BD5.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BD5
Multiples-Based Value
Not Available
Multiples Across Competitors
BD5 Competitors Multiples
BioDelivery Sciences International Inc Competitors
BioDelivery Sciences International Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
B
|
BioDelivery Sciences International Inc
F:BD5
|
499.2m EUR | 3.5 | 6.9 | 11.8 | 14.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
871.6B USD | 13.3 | 42 | 28.3 | 30.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.1B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.4B GBP | 5.2 | 29.9 | 16.5 | 23.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296.9B USD | 4.5 | 15.9 | 9.9 | 12 | |
| CH |
|
Novartis AG
SIX:NOVN
|
230.8B CHF | 5.1 | 20.5 | 12.7 | 16.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 11 | 8.1 | 9.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.1B USD | 2.5 | 19.9 | 7.7 | 10.2 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
89.3B GBP | 2.7 | 15.4 | 8.3 | 10.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
